Boyu Hu
SWOG Cancer Research Network · Huntsman Cancer Institute · UTAH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Boyu Hu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07638722 · Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentSWOG Cancer Research Network · not yet recruiting · Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma · principal investigator
- Ph1/Ph2NCT05405309 · RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaUniversity of Utah · terminated · Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT03843294 · Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaCatherine Bollard · active not recruiting · Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Efforts to Discover Novel Therapies and Reduce Treatment Toxicities for Lymphoma and Chronic Lymphocytic Leukemia Patients Through Collaboration and the NCTNR50CA305062 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2025 · $935,075 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT07638722
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:50 UTC. The ranking covers the 200 most relevant of 294 PubMed records, and a shared surname and initials can bring in a namesake. All 294 on PubMed
- Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.Proc Natl Acad Sci U S A · 2013559 citationsRCR 15.0
- 333 citationsRCR 14.2
- Longitudinal progression trajectory of GFR among patients with CKD.Am J Kidney Dis · 2012270 citationsRCR 9.0
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.N Engl J Med · 2023230 citationsRCR 33.3
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.N Engl J Med · 2017229 citationsRCR 10.0
- Effect of dipyridamole plus aspirin on hemodialysis graft patency.N Engl J Med · 2009220 citationsRCR 6.9
- 168 citationsRCR 6.0
- Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.Lancet Respir Med · 2021167 citationsRCR 7.3
- PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.Circ Res · 2017152 citationsRCR 5.5